21st.BIO
Thomas Kabel is a Senior CFO/M&A Executive, skilled in leading finance/business development initiatives for knowledge-intensive corporates. He has a solid life science track record, having developed acquisitions for Novozymes, as well as developed and divested Glycom. He is passionate about building world-class teams and businesses.